Carisma Therapeutics's primary candidate product, CT-0508, is set to be displayed at this year's 8th annual CAR-TCR conference.

This article summarized the latest R&D progress of Drotaverine Hydrochloride, the Mechanism of Action for Drotaverine Hydrochloride, and the drug target R&D trends for Drotaverine Hydrochloride.

CaN, or Calcineurin, plays a crucial role in the human body as a calcium-dependent protein phosphatase.

Argenx SE is a biopharmaceutical company that was founded in 2008 and is based in Zuid-Holland, Netherlands.

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of STAT3 inhibitors, has initiated dosing of the first patients in its ongoing REVERTIPF trial.

This article summarized the latest R&D progress of Disitamab Vedotin, the Mechanism of Action for Disitamab Vedotin, and the drug target R&D trends for Disitamab Vedotin.

Proton pumps are enzymes found in the stomach lining that play a crucial role in the production of gastric acid.

Founded in 1994, Exelixis, Inc. is a biotechnology company in California focused on the anti-tumor field that has commercialized new drug products.

Genentech announced today that the Phase III ALINA study assessing Alecensa® (alectinib) has achieved its primary endpoint of disease-free survival (DFS) during a pre-determined interim analysis.

Brotizolam is a small molecule drug that targets the GABAA receptor in the nervous system.

JAK inhibitors can inhibit JAK kinases, block the JAK-STAT signaling pathway, and have great therapeutic potential for a variety of diseases including tumors, immune & inflammation···

Amgen Inc. is a biotechnology company dedicated to providing biological therapeutics to patients with serious diseases by discovering, developing, manufacturing, and delivering innovative human therapies.